Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety of Rituximab in Combination With Other Anti-Rheumatic Drugs in Subjects With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria (Stage I):~* Male or female subjects, between 18 and 80 years of age, who have a documented diagnosis of active rheumatoid arthritis (RA) for ≥ 6 months~* Receiving treatment for RA on an outpatient basis~* Have had an inadequate response to at least one non-biological disease-modifying anti-rheumatic drug (DMARD) and have been receiving this DMARD(s) for ≥ 12 weeks prior to baseline, with stable dose greater than or equal to 4 weeks prior to baseline~* Demonstrated tolerability to currently prescribed DMARDs~* If taking a background corticosteroid, use of the corticosteroid must be at a stable dose during the 4 weeks prior to the first day of treatment with rituximab (Day 1)~* Use of one nonsteroidal anti-inflammatory drug (NSAID) is permitted if the dose is stable for ≥ 2 weeks prior to Day 1~Exclusion Criteria (Stage I):~* Rheumatic autoimmune disease other than RA or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome)~* Functional Class IV as defined by the American College of Rheumatology (ACR) Classification of Functional Status in Rheumatoid Arthritis~* History of or current inflammatory joint disease other than RA or other systemic autoimmune disorder~* Diagnosis of juvenile idiopathic arthritis, or juvenile RA, and/or RA before age 16 years~* Any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement) within 12 weeks prior to baseline or planned within 24 weeks of enrollment~* Lack of peripheral venous access~* Significant cardiac or pulmonary disease (including obstructive pulmonary disease)~* Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine, or gastrointestinal disorders that, in the investigator's opinion, would preclude subject participation~* Primary or secondary immunodeficiency (history of or currently active), including known history of human immunodeficiency virus (HIV) infection~* Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) antibiotics within 4 weeks of baseline or completion of oral antibiotics within 2 weeks prior to baseline~* History of medically significant opportunistic infection~* History of serious recurrent or chronic infection~* History of deep space/tissue infection within 52 weeks prior to baseline~* History of cancer, including solid tumors, hematologic malignancies, and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been excised and cured)~* History of significant cytopenias or other bone marrow disorders~* History of alcohol, drug, or chemical abuse within 24 weeks prior to baseline~* Pregnancy or lactation~* Neuropathies and neurovasculopathies that might interfere with pain evaluation~* Methotrexate (MTX) monotherapy at the time of screening~* Concurrent treatment with MTX and leflunomide in combination~* Concurrent treatment with any biologic agent~* Prior to Day 1, subjects will be discontinued from all DMARDs/combinations that are prohibited in the protocol~* History of a severe allergic or anaphylactic reaction to a biologic agent, or known hypersensitivity to any component of rituximab or to murine proteins~* Previous treatment with an anti-α4 integrin agent~* Previous treatment with any cell-depleting therapies, including investigational agents~* Receipt of any vaccine within 28 days prior to baseline~* Intolerance or contraindications to IV corticosteroids~* Receipt of IV immunoglobulin (IVIG) or Prosorba\<TM\> column within 6 months prior to baseline~* Any previous treatment with rituximab~* Positive hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody~Inclusion Criteria (Stage II):~* Male or female subjects, between 18 and 80 years of age, who have a documented diagnosis of active RA for ≥ 6 months, diagnosed according to the revised 1987 ACR criteria for the classification of RA~* Receiving treatment for RA on an outpatient basis~* Have had an inadequate response to at least one biologic DMARD and have been receiving this agent at screening and for ≥ 12 weeks prior to baseline, with stable dose greater than or equal to 4 weeks prior to baseline~* Have demonstrated tolerability to currently prescribed DMARDs/biologics~* If taking a background corticosteroid, use of the corticosteroid must be at a stable dose during the 4 weeks prior to baseline~* Use of one NSAID is permitted if the dose is stable for ≥ 2 weeks prior to baseline~Exclusion Criteria (Stage II):~* Rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA (including but not limited to vasculitis, pulmonary fibrosis, or Felty's syndrome)~* Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis~* History of, or current, inflammatory joint disease other than RA or other systemic autoimmune disorder~* Diagnosis of juvenile idiopathic arthritis, or juvenile RA, and/or RA before age 16 years~* Any surgical procedure, including bone/joint surgery/synovectomy (including joint fusion or replacement) within 12 weeks prior to baseline or planned within 24 weeks of randomization~* Lack of peripheral venous access~* Significant cardiac or pulmonary disease (including obstructive pulmonary disease)~* Evidence of significant uncontrolled concomitant disease such as, but not limited to, nervous system, renal, hepatic, endocrine or gastrointestinal disorders that, in the investigator's opinion, would preclude subject participation~* Primary or secondary immunodeficiency (history of or currently active), including known history of HIV infection~* Known active infection of any kind (excluding fungal infections of nail beds), or any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of baseline or completion of oral antibiotics within 2 weeks prior to baseline~* History of medically significant opportunistic infection~* History of serious recurrent or chronic infection~* History of deep space/tissue infection within 52 weeks prior to baseline~* History of cancer, including solid tumors, hematologic malignancies, and carcinoma in situ (except basal cell and squamous cell carcinoma of the skin that have been excised and cured)~* History of significant cytopenias or other bone marrow disorders~* History of alcohol, drug, or chemical abuse within 24 weeks prior to baseline~* Pregnancy or lactation~* Neuropathies and neurovasculopathies that might interfere with pain evaluation~* Infliximab monotherapy at the time of screening (infliximab should be in combination with MTX)~* Concurrent treatment with MTX and leflunomide in combination~* Concurrent treatment with more than one biologic agent~* Prior to Day 1, subjects will be discontinued from all DMARDs/combinations that are prohibited in the protocol~* History of a severe allergic or anaphylactic reaction to a biologic agent, or known hypersensitivity to any component of rituximab or to murine proteins~* Previous treatment with an anti-α4 integrin agent~* Previous treatment with any cell-depleting therapies~* Treatment with any investigational agent within 28 days of baseline or 5 half-lives of the investigational drug (whichever is the longer)~* Receipt of any vaccine within 28 days prior to baseline~* Intolerance or contraindications to IV corticosteroids~* Receipt of IVIG or Prosorba\<TM\> column within 6 months prior to baseline~* Any previous treatment with rituximab~* Positive hepatitis B surface antigen, hepatitis B core antibody, or hepatitis C antibody~* Positive purified protein derivative (PPD) skin test not adequately treated according to Center for Disease Control (CDC) guidelines

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Rituximab 1000 mg (Stage I patients) (Type: EXPERIMENTAL): Stage I patients received 2 doses of rituximab 1000 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 1000 mg given 14 days apart. Concomitant non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.
- Rituximab 500 mg (Stage II patients) (Type: EXPERIMENTAL): Stage II patients received 2 doses of rituximab 500 mg administered intravenously (IV) 14 days apart at the beginning of the study (Days 1 and 15). During Weeks 24 to 40, patients who met disease activity and safety criteria were eligible to receive 2 additional IV infusions of rituximab 500 mg given 14 days apart. Concomitant biological and non-biological disease-modifying anti-rheumatic drug (DMARD) therapy, at a stable dose and route, was continued during the study, except for protocol defined prohibited DMARDs/combinations.

Based on this trial design, predict the completion outcome and termination type (if applicable).